Ubs Asset Management Americas Inc Protagonist Therapeutics, Inc Transaction History
Ubs Asset Management Americas Inc
- $379 Billion
- Q1 2025
A detailed history of Ubs Asset Management Americas Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 208,756 shares of PTGX stock, worth $11.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
208,756
Previous 287,911
27.49%
Holding current value
$11.4 Million
Previous $11.1 Million
9.16%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding PTGX
# of Institutions
304Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$334 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$315 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.72MShares$312 Million4.53% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$234 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$164 Million5.07% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.68B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...